INTRODUÇÃO: O sucesso a longo prazo da intervenção coronária percutânea, inicialmente realizada apenas com balão, era limitado pelo recolhimento elástico da artéria e pela hiperplasia neointimal. Com o advento dos stents convencionais (BMS) houve melhora nesse cenário e diminuição da reestenose, que é resultante de uma complexa cadeia de eventos iniciada após a injúria causada na parede vascular pela insuflação de balões e da aposição das hastes do stent. A proliferação excessiva de células musculares lisas (VSMC) tem papel fundamental na formação da neoíntima no contexto da reestenose intra-stent com a consequente redução da luz arterial. Com o advento dos stents farmacológicos (DES) houve diminuição importante da hiperplasia neointimal e um dos fármacos que se mostrou efetivo nesse papel é o sirolimo, que atua se ligando à proteína de ligação 12 e o heterodímero resultante se liga à mTOR impedindo sua ativação e causando parada do ciclo celular entre as fases G1 e S, desse modo inibindo a proliferação e migração de VSMC e das células endoteliais (HUVEC). Portanto a intervenção coronária acaba interferindo diretamente no endotélio, interferindo na produção das HUVEC não apenas no aspecto quantitativo, mas também na função das mesmas, e a qualidade funcional do endotélio é tão fundamental quanto à sua presença. Após o implante dos DES, principalmente os de primeira geração, ocorre disfunção endotelial cujo principal marcador é a perda da capacidade do relaxamento do vaso. Há correlação também entre cobertura das hastes incompleta e ocorrência de trombose dos stents. Consequentemente há espaço para o aprimoramento dos DES, para que se tornem dispositivos com eficácia já alcançada na prevenção da reestenose porém com um perfil de segurança maior. O presente trabalho tem como objetivo avaliar as alterações causadas pelos DES nas HUVEC e nas VSMC em cocultura na presença e na ausência do soro rico em plaquetas. MATERIAIS E MÉTODOS: Utilizamos células HUVEC e VSMC em modelos de monocultura e cocultura, na presença e na ausência de soro rico em plaquetas, tratadas com BMS ou DES. Realizamos a determinação da IC50 do inibidor da mTOR, avaliação da citotoxicidade pelo método colorimétrico do MTT, determinação da formação de peróxidos lipídicos, avaliação das fases do ciclo celular e da expressão de marcadores de controle de proliferação e inflamação. RESULTADOS: Na avaliação da citotoxicidade pelo método colorimétrico do MTT e determinação da IC50 as VSMC foram menos sensíveis ao sirolimo que as HUVEC (IC50 em 24/48 horas 14,85/10,47uM e 9,48/22,24 uM, respectivamente para HUVEC e VSMC). As plaquetas e fatores solúveis potencializam o estresse oxidativo gerado pela presença dos stents possivelmente por ampliar o ambiente inflamatório. Houve parada do ciclo celular na fase G0/G1 causada pelos DES somente com adição das plaquetas ao meio de cultura. Nos modelos de cultura celular sem as plaquetas a parada do ciclo celular foi em G2/M. Não houveaumento das células na fase DNA fragmentado (sub-G0) evidenciando que não houve indução de morte celular. CONCLUSÃO: As VSMC foram menos sensíveis ao sirolimo que as HUVEC. Nos modelos de cocultura com adição das plaquetas os DES eluídores de sirolimo causaram parada do ciclo celular na fase G0/G1 sem indução de morte celular, sugerindo que o sirolimo exerce seus efeitos anti-inflamatórios nessas populações celulares e consequentemente reduz a hiperplasia neointimal por um mecanismo citostático / INTRODUCTION: The long-term success of percutaneous coronary intervention, initially performed only with a balloon, was limited by the elastic recoil of the artery and by neointimal hyperplasia. There was improvement in this scenario with the advent of bare metal stents (BMS), because they decrease in restenosis, that resulting from a complex network of events initiated after the injury caused in the vascular wall by insufflation of balloons and apposition of the stent struts. Excessive proliferation of smooth muscle cells (VSMC) plays a key role in neointimal hyperplasia in the context of intrastent restenosis with consequent reduction of arterial lumen. With the advent of drug-eluting stents (DES) there was a significant decrease in neointimal hyperplasia and one of the drugs that proved effective in this role is sirolimus, which acts by binding to the binding protein 12 and the resulting heterodimer binds to mTOR preventing its activation and causing cell cycle arrest between G1 and S phases and thereby inhibiting the proliferation and migration of VSMC and also inhibiting endothelial cells (HUVEC). Therefore, coronary intervention interferes directly in the endothelium, interfering in the production of endothelial cells, not only in the quantitative aspect, but also in their function, and the functional quality of the endothelium is as fundamental as its presence. After the implantation of DES, especially those of the first generation, endothelial dysfunction occurs, whose main marker is the loss of the capacity of the vessel relaxation. There is also correlation between incomplete stem coverage and stent thrombosis. Consequently, it is possible to improve of the DES, so that they become devices with already achieved effectiveness in the prevention of restenosis but with a greater safety profile. The present study aims to evaluate the changes caused by DES in human HUVEC and VSMC in co-culture in the presence and absence of platelet-rich serum. MATERIALS AND METHODS: We used HUVEC and VSMC in monoculture and co-culture models in the presence and absence of platelet rich serum treated with BMS or DES. We performed the determination of IC50 for mTOR inhibitor, cytotoxicity evaluation by the colorimetric method of MTT, determination of lipid peroxide formation, cell cycle and expression of necrosis and inflammation markers. RESULTS: In the assessment of cytotoxicity by the MTT colorimetric method and determination of the IC50, VSMC were less sensitive to sirolimus than HUVEC (IC50 in 24/48 hours 14.85 uM/10.47uM and 9.48 uM/ 22.24 uM, respectively for HUVEC and VSMC). Platelets potentiate the oxidative stress generated by the presence of stents, possibly by increasing the inflammatory environment. Drug-eluting stents arrested VSMC and HUVEC in the G0/G1 phase of the cell cycle only with the addition of platelets to the culture medium. In cell culture models without platelets the cell cycle arrest was in G2/M. There was no increase of the cells in the fragmented DNA phase (sub-G0) evidencing that there was no induction of apoptosis. CONCLUSION: Human aorta smooth muscle cells of the were less sensitive to sirolimus than HUVEC. In coculture models with platelet addition, DES with sirolimus caused cell cycle arrest in the G0/G1 phase without induction of apoptosis, suggesting that sirolimus exerts its antiinflammatory effects in these cellular populations and consequently reduces neointimal hyperplasia via a cytostatic mechanism

O objetivo geral desse estudo foi desenvolver um protótipo de um software para sistema web e dispositivo móvel para orientação de pacientes sobre Cateterismo Cardíaco e Angioplastia de Artéria Coronária. Tratou-se de estudo de Design Instrucional do tipo Design Centrado no Usuário, aplicado à produção tecnológica para desenvolvimento do protótipo de um software em ambiente web e tecnologia móvel, para consulta de informações sobre Cateterismo Cardíaco e Angioplastia de Artéria Coronária. O estudo foi desenvolvido em quatro etapas, cada qual permitindo o alcance dos objetivos específicos. Para tanto construiu-se o conteúdo sobre esses exames, tendo como base um levantamento bibliográfico, buscando pelas evidências científicas existentes sobre o tema. A primeira versão do conteúdo foi elaborada e apresentada a experts na área de cardiologia para refinamento. Após essa etapa, foi construída a segunda versão do protótipo do software, submetida à avaliação de 30 pacientes que estavam agendados no setor de hemodinâmica de uma instituição hospitalar pública e de ensino e pesquisa para a realização dos procedimentos de Cateterismo Cardíaco e de Angioplastia de Artéria Coronária. Esta etapa de coleta de dados foi realizada em 2018. Após esta avaliação, elaborou-se a terceira versão do protótipo do software, que posteriormente será encaminhada aos procedimentos de ilustração e informatização, para o sistema web. O estudo deixa sua contribuição para a área de cardiologia, para as ciências de saúde, em especial para a Enfermagem e para o avanço tecnológico nas ciências da saúde, por ter apresentado um conteúdo seguro e baseado em evidências científicas, direcionado aos pacientes submetidos a esses complexos exames. Sua contribuição refere-se, também, ao avanço de conhecimento sobre o tema para essa população de indivíduos. Sua aplicação indica que é um instrumento importante para a educação em saúde desses pacientes, podendo suprir as necessidades do pouco conhecimento sobre o Cateterismo Cardíaco e a Angioplastia da Artéria Coronária demonstrada por eles / The general objective of this study was to develop a software prototype to web system and mobile devices for patients orientation about Cardiac Catheterism and Coronary Artery Angioplasty. It was an Instructional Design, much like User Centered Design, applied to the technological production for the software prototype development on web environment and mobile technology, to search information about Cardiac Catheterism and Coronary Artery Angioplasty. The study was developed in four stages, each one allowing the attainment of specific objectives. In order to do that, the examination content was built based on bibliographic research, searching for existent scientific evidences related to the theme. The first content version was elaborated and presented to experts in the cardiology field to its refinement. Following after this stage, a second version of the software prototype was built, submitted to the evaluation of 30 patients scheduled at the hemodynamic sector of a public hospital institution, academics and research, in order to conduct the proceedings of Cardiac Catheterism and Coronary Artery Angioplasty. This stage of data collection was carried out in 2018. After this evaluation, a third version of the software prototype was elaborated, which subsequently will be referred to the illustration and computerisation proceedings, to the web system. The study leaves its contribution to the cardiology field, health sciences, especially to nursing and technological advancements in health sciences, for having presented a safe content, based on scientific evidences, directioned to the patients submitted to these complex examinations. Its contribution also relates to the knowledge advancements about the theme to this individual population. Its application indicates to be an important instrument for patients health education, being able to supply the needs for having little knowledge about Cardiac Catheterism and Coronary Artery Angioplasty, demonstrated by them

INTRODUÇÃO: A estratificação de risco, pré intervenção coronária percutânea, é um elemento-chave para auxiliar na tomada de decisão oferecendo o nível de expectativas de resultados imediatos e tardios. Esta investigação tem como objetivo desenvolver o escore DESIRE para predizer o risco de ocorrência de eventos cardíacos maiores(ECM) em pacientes(P) submetidos ao implante de stents farmacológicos(SF) na prática clínica diária. MÉTODOS: Desde 2002 todos os pacientes consecutivos, tratados com 1 SF , foram incluídos no Registro DESIRE (Drug-Eluting Stents In REal world), não-randomizado. Desenvolvemos o escore DESIRE, a partir da análise retrospectiva dos dados dos P incluídos entre janeiro de 2007 e dezembro de 2012 uma vez que esta população representava melhor a prática contemporânea da cardiologia intervencionista. As associações das variáveis com os eventos foram testadas pelos testes chi-quadrado e t de Student. Devido às diferenças entre as fases analisadas, decidimos por dois modelos de predição de riscos: hospitalar (Regressão logística) e tardio (Cox) estimando o tempo até o primeiro evento. Após o desenvolvimento, o escore foi aplicado prospectivamente nos pacientes incluídos entre janeiro de 2013 e dezembro de 2014. As estimativas de risco obtidas foram comparadas às taxas de ECM observadas, validando o escore DESIRE nas duas fases. RESULTADOS: 4.061 P compõem a população do estudo sendo que destes, 2.863 P constituem a coorte B1 que foi utilizada para o desenvolvimento do escore e 1.198 P na coorte B2 na qual o escore foi aplicado e validado. As variáveis e seus respectivos pontos para o escore DESIRE hospitalar que variou de 0 a 37 pontos foram: idade em anos (<=49= 0; 50 - 59=1; 60 a 69=2; 70 a 79=4; <= 80=6); cirurgia de revascularização miocárdica prévia(1); doença vascular periférica (5); insuficiência renal (3); síndrome coronária aguda (3); doença multiarterial (3); ponte de safena (6); lesão com trombo (5) e lesão longa (5). Compuseram o escore DESIRE tardio (0 a 45 pontos) as seguintes variáveis: diabete melito com medicação oral (4) ou com insulina (9); cirurgia de revascularização miocárdica prévia (2); doença vascular periférica (6); síndrome coronária aguda (5); doença multiarterial (4); FE<40% (6); ponte de safena (8) e vaso de pequeno calibre (5). Definimos 3 faixas de risco para cada um dos escores categorizando os pacientes de acordo com a pontuação obtida em baixo, intermediário e alto risco para ECM sendo para a fase hospitalar. Ambos os escores apresentaram acurácia para predizer eventos próxima a 70%. CONCLUSÃO: Baseados em dados do Registro do \"mundo real\" foi possível desenvolver o Escore DESIRE que permitiu a adequada estratificação do risco de eventos cardíacos maiores após o implante de SF, nas fases hospitalar e tardia. A partir destas estimativas de risco é possível consubstanciar as escolhas terapêuticas. / BACKGROUND: Risk stratification before percutaneous coronary intervention is a key element to assist in decision making offering the level of expectations for immediate and late outcomes. This research aims to develop the DESIRE score to predict the risk of major cardiac events (MACE) in patients (P) who underwent drug-eluting stent implantation in daily clinical practice. METHODS: Since 2002 all consecutive patients treated with> 1 SF in a single center were included in the non-randomized DESIRE (Drug-Eluting Stents In the Real world) Registry. We developed the DESIRE score based on a retrospective analysis of the patients included between January 2007 and December 2012, since this population better represented the contemporary practice of interventional cardiology. The associations of the variables with the events were tested by chi-square and Student\'s t tests. Due to the differences between the analyzed phases, we decided on two models of risk prediction: hospital (Logistic Regression) and late (Cox) estimating the time until the first event. After the development, the score was applied prospectively in the patients included between January 2013 and December 2014. The risk estimates obtained were compared to the observed MACE rates, validating the DESIRE score in the two phases. RESULTS: A total of 4,061 patients were included in the study population. Of these, 2,863 P were the B1 cohort that was used for the development of the score and 1,198 P in the B2 cohort in which the score was applied and validated. The variables and their respective points for the hospital DESIRE score ranged from 0 to 37 points were: age in years <=49= 0; 50 - 59=1; 60 a 69=2; 70 a 79=4; <= 80=6); Previous myocardial revascularization surgery (1); Peripheral vascular disease (5); Cronic kidney dysfunction (3); Acute coronary syndrome (3); Multivessel disease (3) Saphenousvenous graft (6); lesion with thrombus (5) and Long lesion (5);The following variables composed the late DESIRE score (0 to 45 points): Diabetes mellitus with oral medication (4) or with insulin (9); previous myocardial revascularization surgery (2); Peripheral vascular disease (6); Acute coronary syndrome (5); Multivessel disease (4); ejection fraction <40% (6); saphenous vein graft (8) and small vessel (5). We defined 3 risk ranges for each of the scores by categorizing the patients according to the low, intermediate and high-risk scores for ECM being for the hospital phase. Both scores had accuracy to predict MACE close to 70%. CONCLUSION: Based on data from the \"real world\" registry, it was possible to develop the DESIRE score that allowed the adequate stratification of the risk of major cardiac events after the SF implantation in the hospital and late phases. From these risk estimates it is possible to substantiate the therapeutic choices.

As doenças cardíacas estão entre as condições crônicas consideradas como desafio para o setor saúde deste século e, nas próximas décadas, continuarão sendo a principal causa de morte global. Dentre as doenças cardiovasculares, a Doença Arterial Coronariana (DAC) é uma das mais importantes causas de morbimortalidade na população adulta. A Intervenção Coronária Percutânea (ICP) é uma das formas de tratamento da DAC. Deve ser acompanhada de medidas terapêuticas farmacológicas e não farmacológicas com o intuito de controlar a sua progressão e melhorar a qualidade de vida relacionada à saúde (QVRS). Objetivo. Comparar as medidas de QVRS e de sintomas de ansiedade e de depressão um ano após à ICP, de acordo com o tipo de intervenção recebida (rotina do serviço ou programa educativo com seguimento por telefone). Método. Estudo observacional, de delineamento longitudinal no qual acompanhamos a evolução dessas variáveis de interesse em pacientes submetidos à primeira ICP, entre agosto/2011 e junho/2012, atendidos em um hospital universitário do interior do Estado de São Paulo e que participaram de um estudo clínico aleatorizado. No estudo de intervenção, 30 pacientes participaram de um Programa Educativo com seguimento por telefone (grupo intervenção-GI) e outros 30 receberam informações de acordo com a rotina do serviço (grupo controle-GC) antes da realização da ICP. Doze meses após a intervenção, avaliamos 56 desses pacientes, sendo 29 do GI e 27 do GC. Os dados foram coletados por entrevistas individuais realizadas durante os retornos ambulatoriais ou nas residências dos participantes A QVRS foi avaliada pelo Medical Outcomes Study: 36-Item Short Form Survey (MOS-SF-36) e os sintomas de ansiedade e depressão pela Hospital Anxiety and Depression Scale (HADS), em suas versões validadas para o português. O teste T de Student para amostras independentes foi utilizado para comparar as medidas obtidas pelos instrumentos, segundo a participação ou não no Programa Educativo. O nível de significância adotado foi de 0,05. Resultados. Assim, como na avaliação feita antes da ICP, os grupos continuaram homogêneos nas caracterizações sociodemográficas obtidas, um ano após a intervenção. No GI, 58,6% eram homens, a média de idade foi de 64,6 anos e a maioria era casada (72,4%). No GC, 51,9% eram do sexo masculino, a média de idade foi 61,3 anos e 70,4% estavam casados. A avaliação da QVRS, 12 meses após a ICP, não mostrou diferenças estatisticamente significantes entre os dois grupos aos compararmos as médias dos oito domínios do SF-36. Em ambos os grupos, o domínio melhor avaliado foi Aspectos Sociais (M= 81,9 GI e M=72,7 GC; p=0,169) e o pior avaliado foi Aspectos Físicos (M= 55,2 GI e M=51,87 GC; p=0,777). Não constatamos diferenças entre os dois grupos também para as medidas de ansiedade (M= 6,33 GI e M=6,31 GC; p=0,981) e de depressão (M= 5,89 GI e M=5,31 GC; p=0,578). Conclusão. A participação em um programa educativo antes da ICP não teve efeito na determinação de uma melhor QVRS e menor presença de sintomas de ansiedade e de depressão, doze meses após a realização da intervenção / Cardiac illnesses figure among the chronic conditions that are considered challenging for this century\'s health sector and, in the upcoming decades, they will continue as the main global cause of death. Among the cardiovascular illnesses, Coronary Artery Disease (CAD) is one of the most important causes of morbidity and mortality in the adult population. Percutaneous Coronary Intervention (PCI) is one way to treat CAD. It should come with pharmacological and non-pharmacological measures to control its progression and improve the health-related quality of life (HRQoL). Objective. To compare the HRQoL measures and anxiety and depression symptoms one year after the PCI, according to the type of intervention received (usual care or educational program with telephone monitoring). Method. Observational study with longitudinal design, in which the evolution of these variables of interest was monitored in patients submitted to the first PCI between August/2011 and June/2012, who were attended at a university hospital in the interior of the State of São Paulo and who participated in a randomized clinical study. In the intervention study, 30 patients participated in an Educative Program with telephone monitoring (intervention group-IG) and 30 others received information according to the usual care (control group-CG) before the PCI. Twelve months after the intervention, 56 of these patients were assessed (being 29 from IG and 27 from CG). The data were collected through individual interviews, held during the outpatient return appointments or at the participants\' homes. The HRQoL was assessed using the Medical Outcomes Study: 36-Item Short Form Survey (MOS-SF-36) and the anxiety and depression symptoms using the Hospital Anxiety and Depression Scale (HADS), in its versions validated for Portuguese. Student\'s t-test for independent samples was used to compare the instrument measures according to the participation or not in the Educative Program. Significance was set at 0.05. Results. Like in the assessment preceding the PCI, the groups remained homogeneous in terms of sociodemographic characteristics one year after the intervention. In IG, 58.6% were male, the mean age was 64.6 years and the majority was married (72.4%). In CG, 51.9% were male, the mean age was 61.3 years and 70.4% were married. The HRQoL assessment 12 months after the PCI did not show statistically significant differences between the two groups when the means on the eight SF-36 domains were compared. In both groups, the best domain was Social Functioning (M= 81.9 IG and M=72.7 CG; p=0.169), while the worst was Physical Functioning (M= 55.2 IG and M=51.87 CG; p=0.777). No differences between the two groups were found for the anxiety (M= 6.33 IG and M=6.31 CG; p=0.981) and depression measures either (M= 5.89 IG and M=5.31 CG; p=0.578). Conclusion. The participation in an educative program before the PCI did not affect the determination of a better HRQoL and the lesser presence of anxiety and depression symptoms twelve months after the interview

Introdução. A dupla antiagregação plaquetária traz benefícios no tratamento do infarto agudo do miocárdio com supradesnivelamento do segmento ST (IAMSST). Há variabilidade intra e interindividual no uso do clopidogrel e isso influencia no benefício do seu uso nesse grupo de pacientes. O objetivo desta pesquisa foi avaliar os efeitos de novo antiagregantes plaquetários (prasugrel e ticagrelor) administrados na sala de emergência (\"upstream\") sobre o resultado angiográfico da angioplastia primária, levando em conta o fluxo coronariano TIMI, o blush miocárdico e a carga de trombo. Métodos. Foi realizado um ensaio clínico, randomizado, cego, com 131 pacientes admitidos com IAMSST. Todos os pacientes receberam ácido acetilsalicílico (AAS). Os pacientes foram randomizados para receber clopidogrel (n=44), prasugrel (n=41) ou ticagrelor (n=46) como dose de ataque ainda na emergência. Todos os pacientes foram submetidos a aspiração manual de trombos. Ao término do procedimento, o resultado angiográfico foi avaliado quanto ao fluxo TIMI, o blush miocárdico e a carga de trombo. Resultados. O fluxo coronariano TIMI >= 1 antes do procedimento foi observado mais frequentemente com o uso de ticagrelor (n = 10, 21,7%) do que com o clopidogrel (n = 1, 2,3%) e prasugrel (n = 5, 12,2%; p = 0,019). O fluxo TIMI coronária no fim do procedimento não diferiu significativamente entre os grupos (p = 0,101). Melhor resultado no que diz respeito ao blush miocárdico foi observada com prasugrel, que produziu um grau de blush III em 85,4% (n = 35) dos pacientes, em comparação com o clopidogrel (54,5%; n = 24) e ticagrelor (67,4%; n = 31; p = 0,025). A carga de trombo pré-procedimento foi maior no grupo de clopidogrel, em que 97,7% (n = 43) dos casos denotaram carga de trombo grau 4/5, enquanto 87,8% (n = 36) do grupo prasugrel tiveram respostas semelhantes, e 80,4% (n = 37) foram observadas no grupo ticagrelor (p = 0,03). Conclusão. Os novos antiagregantes plaquetários ticagrelor e prasugrel parecem exercer efeito sobre o resultado angiográfico dos pacientes submetidos a angioplastia primária. O uso do ticagrelor propiciou menor carga de trombo e um fluxo TIMI melhor no pré-procedimento e o uso do prasugrel ensejou melhor perfusão miocárdica analisada pelo blush miocárdico. Não houve diferença no fluxo angiográfico TIMI pós procedimento / Introduction. Dual antiplatelet therapy has benefits in the treatment of acute myocardial infarction with ST-segment elevation (STEMI). There is variability intra and inter individual in the use of clopidogrel and this influences the benefit of its use in this group of patients. The objective of this research was to evaluate the angiographic results of Upstream Clopidogrel, Prasugrel, or Ticagrelor For Patients Treated With Primary Angioplasty. Methods. A clinical trial was conducted, randomized, double blind, with 131 patients admitted with STEMI. All patients received acetylsalicylic acid (ASA). Patients were randomized to receive clopidogrel (n = 44), prasugrel (n = 41) or ticagrelor (n = 46) as loading dose even in emergency. All patients were submitted to manual thrombus aspiration. At the end of the procedure, the angiographic result was evaluated for TIMI flow, myocardial blush and thrombus burden. Results. A coronary TIMI flow >= 1 before the percutaneous procedure was observed more frequently with the use of ticagrelor (n=10, 21.7%) than with clopidogrel (n=1, 2.3%) and prasugrel (n=5, 12.2%; p=0.019). The coronary TIMI flow at the end of the procedure did not significantly differ between the groups (p=0.101). A better result with respect to myocardial blush was observed with prasugrel, which yielded a blush grade of III in 85.4% (n=35) of patients, compared with clopidogrel (54.5%; n=24) and ticagrelor (67.4%; n=31; p=0.025). The pre-procedural thrombus burden was found to be of a higher grade in the clopidogrel group, in which 97.7% (n=43) of the cases exhibited thrombus burdens grade 4/5, whereas 87.8% (n=36) of the prasugrel group had similar responses, and 80.4% (n=37) were observed in the ticagrelor group (p=0.03). Conclusions. The novel antiplatelet agents represented by ticagrelor and prasugrel appear to have effect on the angiographic outcome of patients undergoing primary angioplasty. The use of ticagrelor led to a smaller thrombus burden and better TIMI flow at the beginning of the procedure and the use of prasugrel produced a better myocardial perfusion analyzed by myocardial blush. There was no difference in post angioplasty TIMI flow

No description available.

<p>Uvod: Pravovremena i pouzdana stratifikacija rizika pacijenata sa akutnim ST eleviranim infarktom miokarda (STEMI) je važna zbog adekvatnog zbrinjavanja ovih bolesnika. Primarna perkutana koronarna intervencija (pPCI) je dovela do značajnog pobolj&scaron;anja ishoda pacijenata sa STEMI, a time moguće i do promene prediktivne važnosti različitih faktora rizika. Jung variabla je jednostavan klinički indeks rizika koji se koristi tokom inicijalne prezentacije pacijenata. Pokazana je prediktivna vrednost Jung varijable za hospitalni mortalitet pacijenata sa STEMI lečenih fibrinolitičkom terapijom, dok uloga Jung varijable u dugoročnoj prognozi pacijenata lečenih putem pPCI nije razja&scaron;njena. Cilj: Dokazati prediktivni značaj i odrediti najbolju vrednost Jung varijable u predviđanju jednogodi&scaron;njeg neželjenog kliničkog ishoda kod pacijenata sa STEMI lečenih pPCI, kao i dokazati njenu validnost na nezavisnoj populaciji. Metode: Sprovedena je prospektivna studija praćenja pacijenata sa STEMI lečenih pPCI tokom godinu dana; primarna studija je sprovedena u Institutu za kardiovaskularne bolesti Vojvodine (IKVBV), a validaciona u Vojnomedicinskoj akademiji (VMA). Ishodi studije: smrtni ishod, akutna srčana insuficijencija (AHF) i zbirni neželjeni ishod. Jung varijabla je računata prema formuli: sistolni krvni pritisak / (srčana frekvencija &times; godine života) &times; 100. Prediktivna vrednost Jung variable i prethodno etabliranih skorova rizika TIMI, PAMI i Zwolle je evaluiarana adekvatnim statističkim metodama. Rezultati: Od 647 pacijenata uključenih u primarnu studiju, umrlo je 70 (10.8%), dok je AHF imalo 42 (6.5%); od 418 pacijenata uključenih u validacionu studiju umrlo je 33 (7.9%), a 52 (12.4%) pacijenta je imalo AHF. U primarnoj studiji Jung variabla je bila prediktor smrtnog ishoda i zbirnog neželjenog ishoda, dok je u validacionoj studiji Jung varijabla bila nezavisni prediktor nastanka AHF (p&lt;0.01). Za mortalitet, Jung variabla &lt;= 2.35 je imala sensitivnost 74.3% i specifičnost 77.3%. U primarnoj studiji, C-statistike i 95% interval poverenja Jung varijable za jednogodi&scaron;nji mortalitet i zbirni neželjeni ishod su bile dobre (0.784 (0.750-0.815) i 0.764 (0.729-0.796)) i poredive sa TIMI, PAMI i Zwolle skorovima (p&gt;0.05). C-statistika za predikciju AHF i zbirnog neželjenog ishoda u validacionoj studiji je bila dobra (0.732 (0.655-0.809) i 0.721 (0.655-0.788)), ali manja u odnosu na ostale ispitivane skorove (p&lt;0.01). Zaključak: Jung varijabla je nezavisni prediktor jednogodi&scaron;njeg smrtnog ishoda i zbirnog neželjenog ishoda pacijenata sa STEMI lečenih pPCI u IKVBV i nezavisni prediktor AHF u validacionoj studiji. Jung varijabla, TIMI, PAMI i ZWOLLE skorovi imaju dobar i porediv diskriminatorni kapacitet za sve praćene ishode u primarnoj studiji, dok je u validacionoj studiji Jung varijabla imala dobar diskriminatorni kapacitet za AHF i zbirni neželjeni ishod, ali manji u odnosu na ostale ispitivane skorove.</p> / <p>Background: Accurate eary risk stratification of patients with ST-elevation myocardial infarction (STEMI) is important in the management of this patients. Primary percutaneous coronary intervention (pPCI) in patients with STEMI has improved the outcome significantly and might have changed the relative contribution of different risk factors. Jung variable is a simple clinical risk index, designed to be used at initial presentation. It is predictive of in hospital mortality in STEMI patients treated with fibrinolysis, but it&#39;s long term predictive power in patients treated with pPCI is not elucidated. Aim: To determine the prognostic accuracy and cut off value of Jung variable for one year clinical outcomes in STEMI patients treated with pPCI, and to validate it in independent STEMI patients. Methods: Two prospective studies of consecutive patients treated with pPCI were conducted; primary study in Institute of Cardiovascular diseases of Vojvodina and validation study in Military medical academy. One-year clinical outcomes (all-cause mortality, acute heart failure (AHF) and combined end point) were assessed. The Jung variable was calculated using the equation: systolic blood/ (heart rate&times;age)&times;100. The predictive value of Jung variable and previously established scores TIMI, PAMI, and Zwolle were evaluated with adequate statistical analyses. Results: Out of 647 patients 70 (10.8%) died and 42 (6.5%) had AHF in primary, while out of 418 patients 33 (7.9%) died and 52 (12.4%) had AHF in validation study. In primary study Jung variable was independent predictor of mortality and combined end point, while it was independent predictor of AHF in validation study (p&lt;0.01). Jung variable &lt;= 2.35 had sensitivity 74.3% and specificity 77.3% for mortality. In a primary study, C-statistic and 95% confidence intervals of Jung variable for one-year mortality and for combined end point were well (0.784 (0.750-0.815) and 0.764 (0.729-0.796), respectively) and comparable to TIMI, PAMI and Zwolle risk score (p&gt;0.05). C-statistic for predicting one-year AHF and combined clinical endpoint in a validation study was well (0.732 (0.655-0.809) and 0.721 (0.655-0.788), respectively), but lower than other risk scores (p&lt;0.01). Conclusion: The Jung variable was independent predictor of one year mortality and combined end point in primary study STEMI patients treated with pPCI and independent predictor of AHF in validation study. The Jung variable, TIMI, PAMI, and Zwolle risk scores performed well and comparable for all clinical outcomes in primary, while in a validation study Jung variable performed well for AHF and combined end point, but significantly lower than other risk scores.</p>

The initial treatment options for patients with stable coronary artery disease include optimal medical therapy alone, or coronary revascularization with optimal medical therapy. The most common revascularization modality is percutaneous coronary intervention (PCI) with either bare metal stents (BMS) or drug-eluting stents (DES). PCI is believed to reduce recurrent angina and thereby decrease the need for additional procedures compared to optimal medical therapy alone. It remains unclear if these benefits are sufficient to offset the increased costs and small increase in adverse events associated with PCI. The objectives of this thesis were to determine the degree of angina relief afforded by PCI and develop a tool to provide contemporary estimates of the impact of angina on quality of life. In addition, we sought to develop a comprehensive state-transition model, calibrated to real world costs and outcomes to compare the cost-effectiveness of initial medical therapy versus PCI with either BMS or DES in patients with stable coronary artery disease. ii We performed a systematic search and meta-analysis of the published literature. Although PCI was associated with an overall benefit on angina relief (odds ratio [OR] 1.69; 95% Confidence Interval [CI] 1.24-2.30), this benefit was largely attenuated in contemporary studies (OR 1.13; 95% CI 0.76-1.68). Our meta-regression analysis suggests that this observation was related to greater use of evidence-based medications in more recent trials. Using simple linear regression, we were able to create a mapping tool that could accurately estimate utility weights from data on the Seattle Angina Question, the most common descriptive quality of life instrument used in the cardiovascular literature. In our economic evaluation, we found that an initial strategy of PCI with a BMS was cost- effective compared to medical therapy, with an incremental cost-effectiveness ratio (ICER) of $13,271 per quality adjusted life year gained. In contrast, DES had a greater cost and lower survival than BMS and was therefore a dominated strategy.

The initial treatment options for patients with stable coronary artery disease include optimal medical therapy alone, or coronary revascularization with optimal medical therapy. The most common revascularization modality is percutaneous coronary intervention (PCI) with either bare metal stents (BMS) or drug-eluting stents (DES). PCI is believed to reduce recurrent angina and thereby decrease the need for additional procedures compared to optimal medical therapy alone. It remains unclear if these benefits are sufficient to offset the increased costs and small increase in adverse events associated with PCI. The objectives of this thesis were to determine the degree of angina relief afforded by PCI and develop a tool to provide contemporary estimates of the impact of angina on quality of life. In addition, we sought to develop a comprehensive state-transition model, calibrated to real world costs and outcomes to compare the cost-effectiveness of initial medical therapy versus PCI with either BMS or DES in patients with stable coronary artery disease. ii We performed a systematic search and meta-analysis of the published literature. Although PCI was associated with an overall benefit on angina relief (odds ratio [OR] 1.69; 95% Confidence Interval [CI] 1.24-2.30), this benefit was largely attenuated in contemporary studies (OR 1.13; 95% CI 0.76-1.68). Our meta-regression analysis suggests that this observation was related to greater use of evidence-based medications in more recent trials. Using simple linear regression, we were able to create a mapping tool that could accurately estimate utility weights from data on the Seattle Angina Question, the most common descriptive quality of life instrument used in the cardiovascular literature. In our economic evaluation, we found that an initial strategy of PCI with a BMS was cost- effective compared to medical therapy, with an incremental cost-effectiveness ratio (ICER) of $13,271 per quality adjusted life year gained. In contrast, DES had a greater cost and lower survival than BMS and was therefore a dominated strategy.

Ziel der Studie war es zu analysieren, welchen Einfluss eine angiographisch sichtbare Kollateralisierung vor Revaskularisation bei Patienten mit einem akuten ST-Elevations-Myokardinfarkt (STEMI) und primärer perkutaner Koronarintervention (PCI) auf verschiedene in der kardialen Magnetresonanztomographie messbare Parameter und auf die klinische Prognose hat. Es wurden 235 Patienten mit STEMI und einem Symptombeginn <12 Stunden in die Analyse eingeschlossen. Alle Patienten wiesen einen funktionell insuffizienten antegraden Fluss in der Infarktarterie auf. Die Patienten wurden in zwei Gruppen unterteilt: Gruppe A mit fehlender oder nur geringer Kollateralversorgung (n=166) und Gruppe B mit einer signifikanten Kollateralisierung (n=69). Es wurden Infarktgröße, mikrovaskuläre Obstruktion und linksventrikuläre Funktion mittels Magnetresonanztomographie im Median 3 Tage nach dem Infarktereignis bestimmt sowie die Patienten über einen Zeitraum von >2 Jahren nachbeobachtet. Das Ausmaß der frühen mikrovaskulären Obstruktion war in Gruppe B signifikant geringer (3,3% gegenüber 2,1% der linksventrikuläre Masse, p = 0,009). Die mittels maximaler Kreatinkinase-MB-Ausschüttung gemessene Infarktgröße war in Gruppe B kleiner (p=0,02). Bei 227 Patienten (97%) wurde nach im Median 2,2 Jahren eine klinische Verlaufskontrolle durchgeführt. Insgesamt starben während des Kontrollzeitraums 25 Patienten: 22 Patienten (13,8%) der Gruppe A mit fehlender oder nur schwacher Kollateralisierung und 3 Patienten (4,4%) der Gruppe B mit signifikanter Kollateralversorgung vor Behandlungsbeginn (p=0,04). In Gruppe A traten 12 (7,5%) nicht-tödliche Reinfarkte auf im Vergleich zu 2 (2,9%) in Gruppe B (p=0,18). Ein kombinierter Endpunkt aus Tod oder nicht-tödlichem Reinfarkt trat in Gruppe B signifikant seltener auf als in Gruppe A (p=0,02). Zusammenfassend lässt sich formulieren, dass gut ausgebildete Kollateralgefäße vor einer Revaskularisation mittels PCI bei Patienten mit akuten STEMI mit einer schützenden Wirkung auf die koronare Mikrozirkulation und einem besseren Langzeit-Überleben assoziiert sind.